926P Real-world data in the era of immune checkpoint inhibitors (ICIs): Cetuximab-containing first-line therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Abstract

Real-world data in the era of immune checkpoint inhibitors (ICIs): Cetuximab-containing first-line therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma